v3.26.1
FINANCIAL INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2026
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash, Cash Equivalents, Restricted Cash Equivalents and Available-for-Sale Securities by Significant Investment Category
The following tables show the Company’s cash, cash equivalents, restricted cash equivalents and available-for-sale securities by significant investment category as of the dates presented:
March 31, 2026
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair ValueCash and Cash Equivalents
Restricted Cash Equivalents
Level 1:
Cash$352,248 $— $— $352,248 $352,248 $— 
Level 2:
Money market instruments2,720,187 — — 2,720,187 1,870,187 850,000 
Total$3,072,435 $— $— $3,072,435 $2,222,435 $850,000 
December 31, 2025
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair ValueCash and Cash Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:
Cash$415,760 $— $— $415,760 $415,760 $— $— 
Level 2:
Money market instruments895,919 — — 895,919 895,919 — — 
Corporate debt securities472,572 3,286 (3)475,855 — 189,566 286,289 
U.S. government agency securities206,018 1,197 (1)207,214 — 59,115 148,099 
Asset-backed securities57,687 420 (4)58,103 — 249 57,854 
Subtotal1,632,196 4,903 (8)1,637,091 895,919 248,930 492,242 
Total$2,047,956 $4,903 $(8)$2,052,851 $1,311,679 $248,930 $492,242 
(1)    The Company’s short-term marketable securities as of December 31, 2025 mature in one year or less, and were liquidated in the first quarter of 2026 to fund the Amicus Therapeutics, Inc. (Amicus) acquisition that closed in April 2026.
(2)    The Company’s long-term marketable securities as of December 31, 2025 mature between one and five years, and were liquidated in the first quarter of 2026 to fund the Amicus acquisition that closed in April 2026.
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents, and restricted cash equivalents reported on the Company’s Condensed Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows:
March 31,
2026
Cash and cash equivalents
$2,222,435 
Restricted cash equivalents
850,000 
Cash, cash equivalents and restricted cash equivalents
$3,072,435 
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents, and restricted cash equivalents reported on the Company’s Condensed Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows:
March 31,
2026
Cash and cash equivalents
$2,222,435 
Restricted cash equivalents
850,000 
Cash, cash equivalents and restricted cash equivalents
$3,072,435